Content about Dopamine agonists

July 16, 2012

UCB launches Neupro transdermal patch

UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday.

April 4, 2012

FDA approves UCB drug for Parkinson's, restless legs syndrome

The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.

February 22, 2012

Study: Prescription-only PSE laws have no impact on number of meth labs, meth abusers

Prescription-only pseudoephedrine regulation has no impact on the methamphetamine trade, according to a Cascade Policy Institute study on the 2005 Oregon law, which restricts access to medicines containing pseudoephedrine.

February 17, 2012

Oklahoma impact study: Rx-PSE would increase health costs without reducing meth issue

According to a report prepared last month by the Economic Impact Group discerning the impact prescription-only pseudoephedrine would have on Oklahoma citizens, prescription-only PSE would result in almost 300,000 additional doctor's office visits at an estimated cost reaching $60 million; $6 million would be directly borne by consumers.

December 14, 2011

Tar Heel State to renew PSE Rx-only debate in two years

North Carolina may be two years away from joining Oregon and Mississippi as the only states to classify pseudoepehdrine as a prescription-only medicine.

September 13, 2011

Survey: Meth use down, thanks to services like NPLEx

Methamphetamine use is down by 50%, even as use of illicit drugs continued to climb between 2008 and 2010, according to a national survey conducted by the Substance Abuse and Mental Health Services Administration that was released last week.

August 15, 2011

Study: Investigational GSK, Impax drug reduces Parkinson's symptoms

Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking standard therapies, according to results of a late-stage clinical trial.

July 26, 2011

Impax enrolls patients into late-stage trial for Parkinson's treatment

The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

January 14, 2011

Kentucky introduces PSE Rx legislation

The battle for the prescription status of methamphetamine precursor/popular cough-cold ingredient pseudoephedrine now is heating up in Kentucky, just a few days following a Nevada news report that suggested the state will be considering PSE prescription-only requirements just as soon as a bill is introduced by Nevada Sen. Sheila Leslie, D-Reno.

March 30, 2010

FDA: Stalevo may increase male patients' risk of cancer

Data from a long-term clinical trial may indicate a possible cancer risk in men taking...

March 22, 2010

Boehringer Ingelheim receives FDA approval for expanded use of Mirapex ER

Less than a month after winning approval for treating early stages of Parkinson’s disease, a...

February 21, 2010

FDA approves Parkinson's disease treatment

The Food and Drug Administration has approved a new treatment for Parkinson’s disease made by...

January 11, 2010

New report projects sales of Parkinson's disease drug will reach $500 million

A drug made by Boehringer Ingelheim for treating Parkinson’s disease could have sales of up...